A critical review of the pharmacology of the plant extract of Pygeum africanum in the treatment of LUTS

Neurourology and Urodynamics

Volumn 26, Issue 4, 2007, Pages 458-463

  Edgar, Alan D ^a   Levin, Robert ^b   Constantinou, Christos E ^c   Denis, Louis ^d  

^a Laboratoires Fournier SA   (France)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Oncology Centre of Antwerp   (Belgium)

Author keywords

Benign prostate hyperplasia; Lower urinary tract; Pygeum africanum

Indexed keywords

GROWTH FACTOR; PYGEUM AFRICANUM EXTRACT;

AGING; ALTERNATIVE MEDICINE; BLADDER DYSFUNCTION; BLADDER FUNCTION; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FIBROBLAST; HUMAN; MOLECULAR INTERACTION; NONHUMAN; PROSTATE HYPERTROPHY; PYGEUM; REVIEW; SIGNAL TRANSDUCTION; SYMPTOM; URINARY TRACT INFECTION;

ANIMALS; HUMANS; MALE; MUSCLE, SMOOTH; PHYTOTHERAPY; PLANT EXTRACTS; PROSTATE; PYGEUM; URINARY BLADDER; UROLOGIC DISEASES;

EID: 34447134091     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.20136     Document Type: Review

References (42)

1. Buk AC. Phytotherapy for the prostate. Br J Urol 1996;78:325-36.
2. Barry MJ, Cockett AT, Holtgrewe HL, et al. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol 1993;150:351-8.
3. Ichiyanagi O, Nakada T. Correlations between parameters in pressure-flow analysis and histological compositions in prostate in patients with benign prostatic hyperplasia. Urol Int 1997;59:154-60.
4. Terris MK, Afzal N, Kabalin JN. Correlation of transrectal ultrasound measurements of prostate and transition zone size with symptom score, bother score, urinary flow rate, and post-void residual volume. Urology 1998;52:462-6.
5. Lowe F. Alpha-1-adrenoceptor blockade in the treatment of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1999;2:110-9.
6. Furuya S, Kumamoto Y, Yokoyama E, et al. Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. J Urol 1982;128:836-9.
7. Oades GM, Eaton JD, Kirby RS. The clinical role of alpha-blockers in the treatment of benign prostatic hyperplasia. Curr Urol Rep 2000;1:97-102.
8. Bautista OM, Kusek JW, Nyberg LM, et al. Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial. Control Clin Trials 2003;24: 224-43.
9. Kaplan SA. 5 alpha-reductase inhibitors: What role should they play? Urology 2001;58:65-70.
10. Levin RM, Longhurst PA, Monson FC, et al. Effect of bladder outlet obstruction on the morphology, physiology, and pharmacology of the bladder. Prostate 1990;Suppl 3:9-26.
11. Levin RW, Brading AF, Mills IW, et al. Experimental models of bladder obstruction. In: Lepor H, editor. Prostatic disease. Philadelphia: W.B. Saunders Co; 2000. pp 169-96.
12. Levin RM, Haugaard N, O'Connor L, et al. Obstructive response of human bladder to BPH vs. rabbit bladder response to partial outlet obstruction: A direct comparison. Neurourol Urodyn 2000;19:609-29.
13. Levine AC, Kirschenbaum A, Gabrilove JL. The role of sex steroids in the pathogenesis and maintenance of benign prostatic hyperplasia. Mt Sinai J Med 1997;64:20-5.
14. Levin RM, Das AK. A scientific basis for the therapeutic effects of Pygeum africanum and Serenoa repens. Urol Res 2000;28:201-9.
15. Gomella LG, Godwin BW, Jr. This month in investigative urology. Apoptosis and benign prostatic hypertrophy. J Urol 1997;158:2-3.
16. Gooren LJ, Toorians AW. Significance of oestrogens in male (patho)physiology. Ann Endocrinol (Paris) 2003;64:126-35.
17. Paubert-Braquet M, Montboisse J-C, Biochot-Lagente E, et al. Pygeum africanum extract (Tadenan) inhibits b-FGF and EGF-induced proliferation of 3T3 fibroblasts. Pharmacologist 1993;35:173.
18. Yablonsky F, Nicolas V, Riffaud JP, et al. Antiproliferative effect of Pygeum africanum extract on rat prostatic fibroblasts. J Urol 1997;157:2381-7.
19. Le Brun G, Mellah I, Aubin P, et al. A rational for the use of Pygeum africanum extract during BPH course is suggested by in vitro proliferation control of human prostate and bladder fibroblasts. Eur Urol 1996;30:98.
20. Solano RM, Garcia-Fernandez MO, Clemente C, et al. Effects of Pygeum africanum extract (Tadenan) on vasoactive intestinal peptide receptors, G proteins, and adenylyl cyclase in rat ventral prostate. Prostate 2000;45: 245-52.
21. Choo MS, Bellamy F, Constantinou CE. Functional evaluation of Tadenan on micturition and experimental prostate growth induced with exogenous dihydrotestosterone. Urology 2000;55:292-8.
22. Buttyan R, Chen MW, Levin RM. Animal models of bladder outlet obstruction and molecular insights into the basis for the development of bladder dysfunction. Eur Urol 1997;32:32-9.
23. Levin RM, Levin SS, Zhao Y, et al. Cellular and molecular aspects of bladder hypertrophy. Eur Urol 1997;1:15-21.
24. Buttyan R, Jacobs BZ, Blaivas JG, et al. Early molecular response to rabbit bladder obstruction. Neurourol Urodyn 1992;11:225-38.
25. Buttyan R, Chen MW, Monson F, et al. Molecular control of rabbit urinary bladder hypertrophy. Biomed Pharmacother 1994;48:27s-34s.
26. Levin RM, Riffaud JP, Bellamy F, et al. Protective effect of Tadenan on bladder function secondary to partial outlet obstruction. J Urol 1996;155: 1466-70.
27. Levin RM, Hass MA, Bellamy F, et al. Effect of oral Tadenan treatment on rabbit bladder structure and function after partial outlet obstruction. J Urol 2002;167:2253-9.
28. Gomes CM, Disanto ME, Horan P, et al. Improved contractility of obstructed bladders after Tadenan treatment is associated with reversal of altered myosin isoform expression. J Urol 2000;163:2008-13.
29. Greenland JE, Hvistendahl JJ, Andersen H, et al. The effect of bladder outlet obstruction on tissue oxygen tension and blood flow in the pig bladder. Brit J Urol 2000;85:1109-14.
30. Greenland JE, Brading AF. The effect of bladder outflow obstruction on detrusor blood flow changes during the voiding cycle in conscious pigs. J Urol 2001;165:245-8.
31. Schroder A, Chichester P, Kogan BA, et al. Effect of chronic bladder outlet obstruction on the blood flow of the rabbit urinary bladder. J Urol 2001;165: 640-6.
32. Levin RM, O'Connor LJ. Leggett RE, et al. Focal hypoxia of the obstructed rabbit bladder wall correlates with intermediate decompensation. Neurourol Urodyn 2003;22:156-63.
33. Levin RM, Whitbeck C, Horan P, et al. Low dose Tadenan protects the rabbit bladder from bilateral ischemia/reperfusion induced contractile dysfunction. Phytotherapy 2005;12:17-24.
34. Valentini FA, Besson GR, Nelson PP. Modelised analysis of the effect of Tadenan on the bladder of patients with BPH: Blind versus open study of uroflows. 5th International Consultation on BPH, Paris; 2000.
35. Zhao Y, Levin SS, Wein AJ, et al. Correlation of ischemia/reperfusion and partial outlet obstruction induced spectrin proteolysis by calpain with contractile dysfunction in the rabbit bladder. Urology 1997;49:293-300.
36. Keast JR, Saunders RJ. Testosterone has potent, selective effects on the morphology of pelvic autonomic neurons which control the bladder, lower bowel and internal reproductive organs of the male rat. Neuroscience 1998;85:543-56.
37. Yoshimura Y, Yamaguchi O, Bellamy F, et al. Effect of Pygeum africanum Tadenan on micturition and prostate growth of the rat secondary to coadministered treatment and post-treatment with dihydrotestosterone. Urology 2003;61:474-8.
38. Griffiths K, Denis L, Turkes A. Prostate and renal cancer, benign prostatic hyperplasia, erectile dysfunction and basic research: An update. In: Bangma C, editor. DWWW. UK: Newliong, Parthenon Publication; 2003. pp 350-79.
39. Paubert-Braquet M, Cave A, Hocquemiller R, et al. Effect of Pygeum africanum extract on A23187-stimulated production of lipoxygenase metabolites from human polymorphonuclear cells. J Lipid Mediat Cell Signal 1994;9:285-90.
40. Terry JG, McGill BL, Crouse JR III. Evaluation of the use of beta-sitostanol as a nonabsorbable marker for quantifying cholesterol absorption. J Lipid Res 1995;36:2267-71.
41. Hass MA, Nowak DM, Leonova E, et al. Identification of components of Prunus africana extract that inhibit lipid peroxidation. Phytomedicine 1999;6:379-88.
42. Dreikorn K. Phytotherapeutic agents in the treatment of benign prostatic hyperplasia. Curr Urol Rep 2000;1:103-9.